(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs

BACKGROUND: To better predict response to immune checkpoint therapy and toxicity in healthy tissues, insight in the in vivo behavior of immune checkpoint targeting monoclonal antibodies is essential. Therefore, we aimed to study in vivo pharmacokinetics and whole-body distribution of zirconium-89 ((...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Veen, Elly L, Giesen, Danique, Pot-de Jong, Linda, Jorritsma-Smit, Annelies, De Vries, Elisabeth G E, Lub-de Hooge, Marjolijn N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537332/
https://www.ncbi.nlm.nih.gov/pubmed/33020241
http://dx.doi.org/10.1136/jitc-2020-000938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537332/
https://www.ncbi.nlm.nih.gov/pubmed/33020241
http://dx.doi.org/10.1136/jitc-2020-000938

Ejemplares similares